Details:

Publisher's site:
http://dx.doi.org/10.15585/mmwr.rr7001a1
Personal Author:
Choi, Mary J., ; Cossaboom, Caitlin M.; ; Whitesell, Amy N. ; ; Dyal, Jonathan W. ; ; Joyce, Allison; ; ... More +
Choi, Mary J., ; Cossaboom, Caitlin M.; ; Whitesell, Amy N. ; ; Dyal, Jonathan W. ; ; Joyce, Allison; ; Morgan, Rebecca L.; ; Campos-Outcalt, Doug; ; Person, Marissa; ; Ervin, Elizabeth et al. Less -
Corporate Authors:
Centers for Disease Control and Prevention (U.S.) ; United States. Advisory Committee on Immunization Practices. ; National Center for Emerging and Zoonotic Infectious Diseases (U.S.) ; McMaster University. Department of Health Research Methods, Evidence, and Impact. ; University of Arizona College of Public Health. ; ... More +
Centers for Disease Control and Prevention (U.S.) ; United States. Advisory Committee on Immunization Practices. ; National Center for Emerging and Zoonotic Infectious Diseases (U.S.) ; McMaster University. Department of Health Research Methods, Evidence, and Impact. ; University of Arizona College of Public Health. ; Baylor College of Medicine. ; University of Washington. ; Saint Louis University School of Medicine. Less -
Description:
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the rVSVΔG-ZEBOV-GP Ebola vaccine (Ervebo) in the United States. The vaccine contains rice-derived recombinant human serum albumin and live attenuated recombinant vesicular stomatitis virus (VSV) in which the gene encoding the glycoprotein of VSV was replaced with the gene encoding the glycoprotein of Ebola virus species Zaire ebolavirus. Persons with a history of severe allergic reaction (e.g., anaphylaxis) to rice protein should not receive Ervebo. This is the first and only vaccine currently licensed by the Food and Drug Administration for the prevention of Ebola virus disease (EVD). These guidelines will be updated based on availability of new data or as new vaccines are licensed to protect against EVD.
Subject:
[+]
Adult
Advisory Committees
Ebola Vaccines
Hemorrhagic Fever, Ebola
Humans

Source:
Recommendations and Reports / January 8, 2021 / 70(1);1–12
Series:
MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and Reports / January 8, 2021 / 70(1);1–12
Document Type:
Journal Issue
Name as Subject:
United States. Food and Drug Administration.
Genre:
Practice Guideline
Place as Subject:
United States
Collection(s):
Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:
[+]
urn:sha256:b3566a1e3c06e3b331b4166e015b7ab9221a739b62af7e1d028522f744254355
File Type:

Supporting Files

• rr7001a1.htm?s_cid=rr7001a1_w

  htm

More +